ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer
- PMID: 40188007
- DOI: 10.1016/j.ijgc.2025.101760
ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer
Abstract
Background: The Laparoscopic Approach to Cervical Cancer trial is the only randomized trial to date addressing the role of surgical approach in cervical cancer; however, this non-inferiority trial of minimally invasive surgery vs an open approach in patients undergoing radical hysterectomy for early-stage cervical cancer did not meet its primary end point of 4.5-year disease-free survival and was terminated early because of significantly worse disease-specific survival, overall survival, and locoregional recurrence in the minimally invasive surgery cohort.
Primary objective: Our trial compares 3-year disease-free survival after robotic-assisted or abdominal radical or simple (in select cases) hysterectomy in early-stage cervical cancer.
Study hypothesis: We hypothesize that disease-free survival is non-inferior after robotic-assisted vs abdominal radical or simple hysterectomy.
Trial design: This multi-center, randomized non-inferiority trial conducted through the Gynecologic Oncology Group has specified surgeon qualification criteria. It requires a pelvic magnetic resonance imaging scan in all patients before enrollment and will use 1:1 randomization to assign patients to robotic-assisted or abdominal hysterectomy. All surgeons must use specified tumor-containment techniques in both arms. It does not allow trans-cervical uterine manipulators.
Major inclusion/exclusion criteria: Patients with early-stage (2018 International Federation of Gynecology and Obstetrics stages IA2-IB2) cervical cancer. Histologic types are limited to squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Pelvic magnetic resonance imaging must confirm a tumor that is 4 cm or less without definitive extra-cervical spread. A simple hysterectomy is allowed in select cases after trial study principal investigator review.
Primary endpoint: The primary end point is the 3-year disease-free survival between robotic-assisted or abdominal hysterectomy.
Sample size: The trial will randomly allocate 840 patients, with planned interim analysis for futility (oncologic safety) after we have randomly allocated 370 and 640 patients.
Estimated dates for completing accrual and presenting results: 2030.
Trial registration: ClinicalTrials.gov identifier: NCT04831580.
Keywords: Cervical Cancer; Radical Hysterectomy; Robotic-Assisted Surgery; Simple Hysterectomy.
Copyright © 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interests M.M.L. Jr: consulting fees: Medtronic; ad-hoc speaker fees: Intuitive Surgical Inc; advisory board participation: JnJ/Ethicon, Immunogen. K.L.B.: none declared. D.M.C.: none declared. A.Q.: speaker honoraria: Merck. C.M.: none declared. D.B.: support for the current study: Intuitive Surgical, Trials365 (Owner); grants or contracts: AstraZeneca, GlaxoSmithKline, Gynecologic Oncology Group, TESARO Inc, Merck; consulting fees: Merck Sharp and Dohme LLC, Pfizer; honoraria: America’s OB/GYN Board Review Course; leadership role: Gynecologic Oncology Group Investigator Council. P.C.L.: honoraria: Intuitive Surgical. R.N.E.: grants or contracts (paid to institution): Clovis Oncology, GSK, Merck, AstraZeneca; consulting fees: AstraZeneca, Clovis Oncology, Eisai, GSK, Daiichi Sankyo, PMV Pharmaceuticals, Nuvectis Pharma, Seagen, Immunogen, Mersana, Myriad, Novocure, Onconova, Elva Therapeutics, Regeneron; speaker honoraria: AstraZeneca, GSK, Immunogen, Merck, Medscape, CURIO, Great Debates and Updates; advisory board: AstraZeneca, Clovis Oncology, Eisai, GSK, Daiichi Sankyo, PMV Pharmaceuticals, Nuvectis Pharma, Seagen, Immunogen, Mersana, Myriad, Novocure, Onconova, Elva Therapeutics, Regeneron; leadership role: GOG P, Clearity Foundation. W.H.G.: grants or contracts: Intuitive Surgical Inc, EISAI, Merck; consulting fees: GSK; speaker honoraria: Intuitive Surgical Inc; expert testimony in lawsuits; monitoring board: GOG ROCC (present work); unpaid leadership role: Israel Cancer Research Fund S.L.: monitoring board: GOG-4043 (steering committee; present work). M.A.M.: consulting fees: Medtronic, Intuitive, J&J, Vivimed Incision; leadership role: Society of Robotic Surgery (past president), I.J.E. (board). J.L.W.: none declared. L.J.C.: grants or contracts (paid to institution): Abbvie/Imunogen, Agenus, Genmab, NRG Oncology, Genentech/Roche, NovoCure, Seattle Genetics; consulting fees: GOG Foundation, ImmunoCore, A28 Therapeutics, Elevar Therapeutics, Luzsana Biotechnology, ImmunoGen, InxMed, OncoNova; travel support: GOG Foundation; advisory board: Immunogen/Abbvie/Iqvia, Corcept; leadership role: GOG Foundation (immediate past president, BOD). B.J.M.: leadership role: GOG Foundation (V.P., B.O.D.). L.M.R.: grants or contracts (paid to institution): Merck, Karyopharm, Akeso, Seagen, Genmab, Acrivon, GOG Foundation, Aravive, AbbVie (Immunogen); consulting fees: GOG Foundation, AstraZeneca, Merck, GSK, Seagen, Natera, Pfizer; speaker honoraria: OncLIve, Curio Science, Seagen, Genmab; travel support: GOG Foundation; leadership role: GOG Foundation; receipt of equipment, materials, drugs, medical writing, gifts, or other services: Merck.
